Pharmacotherapy of Giardiasais: Past, Present & Future
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Expert Review 2
2021 Expert Committee on Selection and Use of Essential Medicines Application review I.1 Albendazole, mebendazole and praziquantel for the indication of treatment of (item number) taeniid cestode cysts Does the application adequately ☒ Yes address the issue of the public health ☐ need for the medicine? No ☐ Not applicable Comments: The larval stages of three taeniid cestode parasites, Echinococcus granulosus, Echinococcus multilocularis and Taenia solium, produce cysts in humans that are of medical relevance. The diseases caused by these parasitic cysts are called cystic echinococcosis (CE), alveolar echinococcosis (AE), and cysticercosis (being neurocysticercosis (NCC) the most common form) respectively, and they are recognised by WHO as neglected tropical diseases. NCC is mainly a disease of poverty that predominantly affects rural populations in Africa, Asia and Latin America. Access to diagnostic and treatment, to better manage epilepsy and other NCC is a challenge for the people affected in these communities due to the availability and costs of specialised diagnostic and care. Stigma and social discrimination also mean that many people try to “hide” the disease. Briefly summarize the role of the The only real options for treatment of CE are albendazole (ALB) and Mebendazole proposed medicine(s) relative to other (MEB). ALB is the drug of choice as it has better bioavailability. ALB is also preferred to therapeutic agents currently included in MEB, because MEB requires a higher dose and a higher pill burden, for example, an the Model List, or available in the adult patient would require 8 tablets/day of MEB compared with 2 tablets/day ALB. market. ALB and praziquantel ( PZQ) are the only drugs used for the antiparasitic treatment of NCC. -
ALBENDAZOLE (Extrapolation to All Ruminants)
European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/865/03-FINAL June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE ALBENDAZOLE (Extrapolation to all ruminants) SUMMARY REPORT (3) 1. Albendazole is a benzimidazole carbamate, used for the treatment of gastrointestinal infestations with roundworms, lungworms and tapeworms and adult flukes of Fasciola hepatica. Albendazole is currently entered into Annex I of Council Regulation (EEC) No. 2377/90 in accordance with the following table: Pharmacologically Marker residue Animal MRLs Target Other active substance(s) species tissues provisions Albendazole Sum of albendazole Bovine, 100 µg/kg Muscle sulphoxide, ovine 100 µg/kg Fat albendazole sulphone 1000 µg/kg Liver and albendazole 2- 500 µg/kg Kidney amino sulphone 100 µg/kg Milk expressed as albendazole 2. In reviewing the availability of endo- and ectoparasiticides for sheep and goats, albendazole was considered for extrapolation from bovine and ovine species to all ruminants. The considerations and criteria leading to the identification of albendazole are described in the Position Paper Regarding Availability of Veterinary Medicines – Extrapolation of MRLs (EMEA/CVMP/457/03-FINAL). 3. The scientific justification for this extrapolation was assessed in accordance with the Notes for Guidance on Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin (EMEA/CVMP/187/00-FINAL) and on the Establishment of Maximum Residue Limits for Minor Animal Species (EMEA/CVMP/153a/97-FINAL). 4. In setting the ADI in the original assessment of albendazole, the data summarised on the paragraphs below were considered. 5. The mode of action of albendazole is by binding strongly with the tubulin in the cells of nematodes. -
Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study
Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al. -
Study Assessing Prices, Availability and Affordability of Children's
Study assessing prices, availability and affordability of children’s medicine in Chhattisgarh, India Part of the Better Medicine for Children project Authors Dr Antony KR Virendra Jain Puni Kokho Dr Kamlesh Jain The salient findings and views expressed in this report are solely those of the authors. Please direct correspondence to the authors: ([email protected], [email protected] [email protected], [email protected]). This publication does not necessarily represent the decisions or policies of the World Health Organization. ii Contents Acknowledgements ........................................................................................... v Abbreviations ................................................................................................... vi Executive summary ......................................................................................... vii Medicine availability .............................................................................................vii Medicine costs ................................................................................................... viii Affordability of standard treatment regimens ........................................................... ix Price components survey ...................................................................................... ix Conclusion .......................................................................................................... x 1. Introduction ................................................................................................. -
Valbazen ® (Albendazole)
® (albendazole oral suspension) Broad-Spectrum Dewormer Oral Suspension for Use in Cattle, Sheep, and Goats for removal and control of liver flukes, tapeworms, stomach worms (including 4th stage inhibited larvae of Ostertagia ostertagi), intestinal worms, and lungworms in cattle and sheep and for the treatment of adult liver flukes in nonlactating goats Active Ingredient Albendazole ............................. 11.36% (equivalent to 113.6 mg/mL) 1 L/33.8 fl oz (1 qt 1.8 fl oz) Approved by FDA under NADA # 110-048 40029175 ® (albendazole oral suspension) Broad-Spectrum Dewormer Oral Suspension for Use in Cattle, Sheep, and Goats for removal and control of liver Indications: flukes, tapeworms, stomach worms (including 4th stage inhibited larvae of Ostertagia Cattle and sheep: Valbazen is a broad-spectrum anthelmintic effective in the removal ostertagi), intestinal worms, and lungworms in cattle and sheep and for the treatment and control of liver flukes, tapeworms, stomach worms (including 4th stage inhibited of adult liver flukes in nonlactating goats larvae of Ostertagia ostertagi ), intestinal worms, and lungworms as indicated below. Active Ingredient: Goats: For the treatment of adult liver flukes in nonlactating goats. Albendazole .......................................................... 11.36% (Equivalent to 113.6 mg/mL) Parasite Cattle Sheep Goats Adult Liver Flukes Fasciola hepatica Fasciola hepatica, Fascioloides magna Fasciola hepatica Heads and Segments Moniezia benedeni, M. expansa Common Tapeworm (Moniezia expansa), Fringed Tapeworm of Tapeworms (Thysanosoma actinioides) Adult and 4th Stage Brown Stomach Worm, including 4th stage Brown Stomach Worm (Ostertagia circumcincta, Marshallagia Larvae of Stomach inhibited larvae (Ostertagia ostertagi), marshalli), Barber Pole Worm (Haemonchus contortus), Small Worms Barber Pole Worm (Haemonchus Stomach Worm (Trichostrongylus axei) contortus, H. -
Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Helicobacter Pylori Infection: a Systematic Review and Meta-Analysis
Original Article Gastroenterol Res. 2020;13(6):260-268 Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis Umair Iqbala, g, Harshit S. Kharaa, Daud Akhtarb, Yirui Huc, Hafsa Anward, Khwaja F. Haqe, Hafiz U. Siddiquif, Marika K. Bergenstocka, Matthew J. Shellenbergera Abstract eradication regimens revealed a pooled eradication rate of 85% (95% CI: 69-94%) without heterogeneity. In a subgroup analysis, highest Background: Helicobacter pylori (HP) is the most common cause of eradication rates were achieved with levofloxacin, doxycycline, nita- gastritis worldwide. Clarithromycin-based triple therapy or bismuth- zoxanide and proton pump inhibitor with a pooled eradication rate of based quadruple therapy is usually considered the first-line treatment, 92% (88-95%). however with around 30% failure rate for both regimens. Drug re- Conclusion: Nitazoxanide-based regimen is safe and effective in the sistance of clarithromycin and metronidazole is a growing concern eradication of HP infection. It is also successful as a salvage therapy in some parts of the world. Therefore, there is a need for effective in patients who have failed prior treatments. eradication regimen for HP. Nitazoxanide, a bactericidal thiazolide antibiotic, has been shown to be effective in HP infection. We con- Keywords: Nitazoxanide; Helicobacter pylori; Eradication regimen; ducted a systematic review and meta-analysis to evaluate the efficacy Meta-analysis of nitazoxanide-based regimen for the eradication of HP. Methods: We have searched PubMed, Embase, Ovid Medline and Cochrane library database from inception to December 9, 2020 to identify studies that utilized nitazoxanide in the treatment regimen Introduction for HP eradication. -
Albendazole: a Review of Anthelmintic Efficacy and Safety in Humans
S113 Albendazole: a review of anthelmintic efficacy and safety in humans J.HORTON* Therapeutics (Tropical Medicine), SmithKline Beecham International, Brentford, Middlesex, United Kingdom TW8 9BD This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole’s use as an anthelminthic in humans. Cure rates and % egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400 mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400 mg. Overall cure rates are also presented separately for studies involving only children 2–15 years. Similar tables are also provided for the recommended dose of 400 mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and\or spontaneously reported to the company. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just "1%. Albendazole’s unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92% for A. duodenale in 23 studies and 75% for N. -
Treatment Outcomes with Nitazoxanide in Immunocompetent
dicine & Me S l u a r ic g e p r o y r T Ali and Kumar, Trop Med Surg 2015, 3:4 Tropical Medicine & Surgery DOI: 10.4172/2329-9088.1000198 ISSN: 2329-9088 Research Article Open Access Treatment Outcomes with Nitazoxanide in Immunocompetent Adults Naive Patients with Cryptosporidiosis; Do We Need Combination Therapy with Paromomycin or Azithromycin? Sajjad Ali1* and Sunil Kumar2 1Chairman Infection Prevention and Control Department, Department of Internal Medicine/Infectious Diseases, Sultan Bin AbdulAziz Humanitarian City Hospital, Riyadh, Saudi Arabia 2Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi, Pakistan *Corresponding author: Sajjad Ali, Chairman Infection Prevention and Control Department, Department of Internal Medicine/Infectious Diseases, Sultan Bin AbdulAziz Humanitarian City Hospital, Riyadh, Saudi Arabia, Tel: 00966115620000; E-mail: [email protected] Received date: September 16, 2015, Accepted date: October 16, 2015, Published date: October 19, 2015 Copyright: © 2015 Sajjad, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: Human cryptosporidiosis is caused by infection with Cryptosporidium. Nitazoxanide has shown activity against cryptosporidium. The objective of this study is to see treatment outcomes with 7 days of nitazoxanide in immunocompetent adult patients diagnosed with cryptosporidiosis and to consider combination therapy which includes nitazoxanide with paromomycin or azithromycin? Study Design: This cross sectional study was conducted at Sindh Institute of Urology and Transplantation, Karachi Pakistan. Patients were not enrolled with prior diagnosis of cryptosporidiosis and/or had taken Nitazoxanide, Paromomycin or Azithromycin in last 4 weeks prior their diagnosis. -
Comparative Genomics of the Major Parasitic Worms
Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................ -
Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from in Vitro Inhibition of Metabolism
The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from In Vitro Inhibition of Metabolism Author(s): David E. Moody, Ph.D. Document No.: 250127 Date Received: July 2016 Award Number: 2011-DN-BX-K532 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this federally funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. February 2016 Research and Development in Forensic Toxicology Prediction of drug interactions with methadone, buprenorphine and oxycodone from in vitro inhibition of metabolism Final Technical Report Submitted electronically to: U.S. Department of Justice Office of Justice Programs National Institute of Justice Prepared by: David E. Moody. Ph.D. Director of the Center for Human Toxicology, and Research Professor of Pharmacology and Toxicology [email protected] / 801-581-5117 NIJ Award Number: 2011-DN-BX-K532 Reporting Period: January 1, 2012 to December 31, 2015 Recipient Organization: University of Utah 75 South 2000 East, Room 222 Salt Lake City, UT 84112-8930 Organizational DUNS: 0090953650000 EIN: 876000525 This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. -
An Important Advance in Anti-Parasitic Therapy
Am. J. Trop. Med. Hyg., 68(4), 2003, pp. 382–383 Copyright © 2003 by The American Society of Tropical Medicine and Hygiene EDITORIAL NITAZOXANIDE: AN IMPORTANT ADVANCE IN ANTI-PARASITIC THERAPY A. CLINTON WHITE, JR. Infectious Diseases Section, Department of Medicine, Baylor College of Medicine, Houston, Texas The field of anti-parasitic drugs has had a shaky history. maceuticals, Inc. (Marietta, GA) and focused on develop- The major pharmaceutical companies have increasingly fo- ment of the drug for treatment of cryptosporidiosis in ac- cused their drug development efforts on the major markets, quired immunodeficiency syndrome. Controlled trials began with potential annual sales of at least $100 million. This has shortly after the advent of effective anti-retroviral therapies. not worked well for development of anti-parasitic drugs. Most The trials were abandoned due to poor enrollment and the patients develop parasitic infections due to poverty. Thus, Food and Drug Administration rejected an application based while there may be millions of cases in developing countries, on uncontrolled studies. the number able to support the high prices of branded drugs Rather than abandon their efforts, Romark launched an is small. A few new drugs have come into the market. For impressive series of controlled trials. No other agent has example, mefloquine, albendazole, ivermectin, and atova- proven efficacy in the treatment of cryptosporidiosis. How- quone-proguanil have all come to the U.S. market since 1990. ever, a placebo-controlled study of nitazoxanide in cryptospo- However, even this limited number of new drugs is somewhat ridiosis demonstrated significant clinical improvement in deceiving. Mefloquine and atovaquone-proguanil are largely adults and children with mild illness.4 Among malnourished supported by their use in malaria prophylaxis. -
PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use ALINIA ______DOSAGE FORMS and STRENGTHS ______Safely and Effectively
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALINIA _____________ DOSAGE FORMS AND STRENGTHS ______________ safely and effectively. See full prescribing information for ALINIA. ALINIA Tablets: 500 mg (3.1) ALINIA for Oral Suspension: 100 mg/5 mL (3.2) ALINIA® (nitazoxanide) tablets, for oral use ALINIA® (nitazoxanide) for oral suspension ___________________ CONTRAINDICATIONS ___________________ Initial U.S. Approval: 2002 Hypersensitivity (4.1) __________________ _________________ INDICATIONS AND USAGE ___________________ ADVERSE REACTIONS ___________________ ALINIA is an antiprotozoal indicated for the treatment of diarrhea caused by The most common adverse reactions in ≥2% of patients were abdominal pain, Giardia lamblia or Cryptosporidium parvum (1). headache, chromaturia, and nausea (6.1). Limitations of Use: ALINIA has not been shown to be effective for the treatment of diarrhea To report SUSPECTED ADVERSE REACTIONS, contact Romark at caused by C. parvum in HIV-infected or immunodeficient patients (1). 813-282-8544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ___________________ ____________________ _______________ DOSAGE AND ADMINISTRATION ______________ DRUG INTERACTIONS ALINIA Tablets should not be administered to pediatric patient 11 years of Competition for binding sites may occur when administered concurrently with age or younger (2.1). other highly plasma protein-bound drugs with narrow therapeutic indices. Dosage for treatment of diarrhea caused by G. lamblia or C. parvum (2.1): Monitor for adverse reactions (7). Age Dosage Duration ______________ USE IN SPECIFIC POPULATIONS _______________ 5 mL of ALINIA for Oral Suspension Pediatric Patients: Safety and efficacy of ALINIA for Oral Suspension in 1-3 years (100 mg nitazoxanide) every 12 hours with food pediatric patients less than one year of age has not been studied (8.4).